Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831792 · ClinicalTrials.gov registry record · Phase 2
TKI258 in Castrate Resistant Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00831792: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00831792 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00831792, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones. Researchers also want to learn how changes in your blood PSA level might affect the rebuilding of healthy bones while you are being treated with TKI258 for prostate cancer.
Interventions
- DRUG TK1258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2010-04-07 |
| Est. Completion | 2017-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831792
The ClinicalTrials.gov registry entry for NCT00831792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TK1258 is the first listed.
NCT00831792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831792 about?
NCT00831792 is a clinical study titled "TKI258 in Castrate Resistant Prostate Cancer". The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones. Researchers also want to learn how changes in your blood PSA level might affect the rebuilding of healthy...
What is the current status of trial NCT00831792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2010-04-07. Estimated completion is 2017-06-12.
What interventions are being tested in trial NCT00831792?
The interventions under investigation include: TK1258 (DRUG).
Who is sponsoring clinical trial NCT00831792?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.